Ó³»­´«Ã½

In the early 2000s, Ó³»­´«Ã½ researchers found that the EGFR protein is mutated in lung cancer, sparking a revolution in targeted cancer treatment. But not all lung tumors respond to such treatments, leaving many patients with few options. In this Ó³»­´«Ã½ Discovery Series event, Heidi Greulich and Matthew Meyerson will describe the 20-year history of sevabertinib, a new lung cancer drug (and the first FDA-approved drug born of Ó³»­´«Ã½ science) that blocks both EGFR and the related HER2 protein; talk about the unmet need it fulfills, discuss the unique partnership behind its development, and explore drug development's evolving challenges.

Learn more about the Ó³»­´«Ã½ Discovery Series.